SciFluor Life Sciences, a Boston-based developer of technology for adding fluorine to organic molecules such as pharmaceutical drugs and commercial chemicals, launched today with $5 million in funding from Allied Minds. The technology, which helps make molecules more stable, potent, and better able to penetrate the blood-brain barrier, comes from Harvard University’s professor Tobias Ritter and others in the school’s department of chemistry and chemical biology. SciFluor has an exclusive license on fluorination technology and a group of novel fluorinated compounds from Harvard.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
